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Background. Neutrophil dysfunction in sepsis has been implicated in the pathogenesis of multiorgan failure; however, the role of
neutrophil extracellular traps (NETs) remains uncertain. We aimed to determine the sequential changes in ex vivo NETosis and
its relationship with mortality in patients with sepsis and severe sepsis. Methods. This was a prospective observational cohort
study enrolling 21 healthy age-matched controls and 39 sepsis and 60 severe sepsis patients from acute admissions to two
UK hospitals. Patients had sequential bloods for the ex vivo assessment of NETosis in response to phorbol-myristate acetate
(PMA) using a ﬂuorometric technique and chemotaxis using time-lapse video microscopy. Continuous data was tested for
normality, with appropriate parametric and nonparametric tests, whilst categorical data was analysed using a chi-squared
test. Correlations were performed using Spearman’s rho. Results. Ex vivo NETosis was reduced in patients with severe sepsis,
compared to patients with sepsis and controls (p = 0 002). PMA NETosis from patients with septic shock was reduced
further (p < 0 001) compared to controls. The degree of metabolic acidosis correlated with reduced NETosis (p < 0 001), and
this was replicated when neutrophils from healthy donors were incubated in acidotic media. Reduced NETosis at baseline
was associated with an increased 30-day (p = 0 002) and 90-day mortality (p = 0 014) in sepsis patients. These ﬁndings were
accompanied by defects in neutrophil migration and delayed apoptosis. Resolution of sepsis was not associated with the
return to baseline levels of NETosis or migration. Conclusions. Sepsis induces signiﬁcant changes in neutrophil function with
the degree of dysfunction corresponding to the severity of the septic insult which persists beyond physiological recovery from
sepsis. The changes induced lead to the failure to eﬀectively contain and eliminate the invading pathogens and contribute to
sepsis-induced immunosuppression. For the ﬁrst time, we demonstrate that reduced ex vivo NETosis is associated with poorer
outcomes from sepsis.
1. Introduction
The incidence of sepsis is continuing to rise and accounts for
approximately 215,000 deaths per year in the United States of
America (USA) [1]. The management of sepsis places a large
ﬁnancial burden on health care systems with conservative
estimates suggesting that the USA spends $17 billion treating
sepsis annually [1–3].
Sepsis is a complex syndrome that has been deﬁned as a
life-threatening immune response to infection [4]. However,
the pathogen load and its virulence and the subsequent host
characteristics determine the extent and nature of this
response [2, 5]. Neutrophils are one of the ﬁrst lines of defense
against invading pathogens and are responsible for containing
and eliminating invading pathogens [6, 7]. Neutrophils are
multifaceted innate immune cells that also modulate the
inﬂammatory response and initiate the adaptive immune
responses to sepsis via the release of cytokines. It is this coordi-
nated response that maintains immune homeostasis [8].
In sepsis, there is a dysregulated immune response with
activated circulating neutrophils releasing cytokines and
reactive oxygen species (ROS) at sites distal to the infectious
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focus leading to multiorgan failure [7]. Additionally, neutro-
phils have been shown to demonstrate immunosuppressive
phenotypes, with immaturity and altered chemokine expres-
sion responsible for some of these alterations [8]. This has
pertinence in sepsis, with sepsis-induced immunosuppres-
sion being recognized as a clinical syndrome in survivors of
sepsis, who have an increased susceptibility to nosocomial
infections, frequent hospital readmissions, and subsequently
increased late mortality [7, 9–11]. Recently, we described a
reduction in systemic neutrophil migratory accuracy in lower
respiratory tract infections, pneumonia, and a mild, ward-
based pneumonia-associated sepsis cohort with evidence of
prolonged migratory dysfunction after the septic event [12].
It is unclear whether reduced neutrophil migratory accuracy
might also be a feature of a more severe sepsis cohort, how
this might change over time, and whether other facets of neu-
trophil function might also be aﬀected.
Following activation, triggered either by frustrated
phagocytosis or sustained inﬂammation, neutrophils release
neutrophil extracellular traps (NETs), whereby nuclear
DNA laden with histones and granular contents are liberated
into the extracellular space, which trap and kill extracellular
bacteria [13, 14]. The exact role of NETs in sepsis remains
uncertain. Studies in murine models of sepsis have shown
that an inability to generate NETs in response to infection
leads to increased severity of insult and death [14–17]. Addi-
tionally, similar studies have demonstrated that NET forma-
tion in intravascular beds, such as liver sinusoids, and within
the alveoli causes endothelial damage and leads to patterns of
organ dysfunction which are the hallmark of sepsis [18–22].
However, studies linking poor clinical outcomes with neutro-
phil functions, and the production of NETs in patients with
sepsis over time, are lacking.
One of the hallmarks of sepsis is tissue hypoperfusion
and tissue hypoxia leading to a switch to anaerobic glycolysis
and the development of a metabolic lactic acidosis, with the
degree of metabolic acidosis often used as a surrogate marker
for severity of the inﬂammatory/infectious insult [4]. The
role of acidosis in dysregulated neutrophil function in sepsis
is poorly understood.
We hypothesized that sepsis severity (clinical and bio-
chemical) would be associated with impairment of neutro-
phil functions, and in particular NETs, with worse clinical
outcomes being seen in patients with most evidence of innate
immunoparesis. Additionally, we hypothesized that the
severity of acidosis would also be related to NET suppression.
To test this, we aimed to assess neutrophil functions in
patients hospitalized with sepsis and relate this to markers
of sepsis severity and short and long-term clinical outcomes.
2. Materials and Methods
Adult patients admitted to ahospitalwith sepsiswere screened
and enrolled within 48 hours of admission to hospital. Sepsis,
severe sepsis, and septic shock were deﬁned based on the
criteria used by the Surviving Sepsis Campaign Guidelines of
2008 (online Supplementary Materials available here) [23].
Patients were recruited from the University Hospital Bir-
mingham and the Heart of England NHS Foundation Trust
between September 2012 and June 2014 with 1-year follow-
up completed in June 2015. Patients had blood drawn on
enrollment and where possible on day 4 and day 7. Healthy
aged controls (≥60 years with no systemic disease or only
mild systemic disease; stage 1 hypertension/mild asthma)
were also recruited.
This study was carried out per the Declaration of Hel-
sinki, and all patients and healthy controls were consented.
Patients were consented, and where not possible, assent was
gained from their next of kin or physician. These studies
received appropriate ethical approvals (Regional Ethics
Committee references: 11/SC/0356 and 11/YH/0270). This
research was undertaken prior to the publication of the new
sepsis deﬁnitions of 2015. The new deﬁnitions identify a pop-
ulation at high risk of in-hospital mortality, but exclude
milder infections, which this study sought to include [4].
2.1. Isolation of Neutrophils. Neutrophils were isolated on a
Percoll (pH8.5–9.5; Sigma-Aldrich, UK) density gradient as
previously described [24, 25]. The neutrophils (95% pure
and 97% viable by trypan blue exclusion) were resuspended
in RPMI 1640 (Sigma-Aldrich).
2.2. Neutrophil Extracellular Trap Assay. Freshly isolated
neutrophils (1× 105 cells) were stimulated to generate NETs
by incubating them within the control media (RPMI 1640
supplemented with glutamine, penicillin, and streptomycin-
GPS; Sigma-Aldrich) or in the positive control 25nM
phorbol-myristate acetate (PMA, Sigma-Aldrich) as previ-
ously described using aﬂuorometric technique [26].NETpro-
duction was measured as arbitrary ﬂuorescent units (AFUs).
2.3. Neutrophil Migration Assay. Migration was assessed
using an Insall Chamber (Weber Scientiﬁc International
Ltd., UK) as described previously [27, 28]. Migration was
assessed towards a vehicle control (RPMI 1640), 100 nM
interleukin-8 (CXCL-8) (R&D Systems, UK). Time-lapse
video microscopy was used to capture neutrophil migration
and analysed using ImageJ vector analysis software (Wayne
Rasband, Bethesda) to calculate chemotaxis (directional
migration) [12].
2.4. Cell-Free DNA Measurement. Cell-free DNA (cf-DNA)
levels were measured from stored plasma samples using a ﬂu-
orometric assay and SYTOX Green Dye (Life Technologies,
UK) as previously described [29]. Values are represented as
ng/ml of cf-DNA.
2.5. Neutrophil Apoptosis Assay. Freshly isolated neutrophils
(1× 105 cells) were suspended in RPMI 1640 supplemented
with GPS. Apoptosis experiments were performed by ﬂow
cytometry (CyaNADP; Beckham Coulter) on isolation, at
4 hours and 24 hours.
To account for variations in baseline rates of apoptosis,
the percentage change in apoptosis at 4 hours and 24 hours
was calculated.
2.6. Statistical Analysis. Statistical analysis was performed
using GraphPad Prism Version 6 (La Jolla, USA). Continu-
ous data was tested for normality using a Shapiro-Wilk test.
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Parametric data are represented as mean ± SEM and were
analysed using a Student’s t-test (two independent samples)
or a one-way analysis of variance (ANOVA) test with a post
hoc Bonferroni test (more than 2 groups). Nonparametric
data are represented as median (IQR) and were analysed with
a Mann–Whitney U test (two independent samples) or a
Kruskal-Wallis test (more than 2 groups) with Dunn’s post
hoc test. A Pearson or Spearman correlation was used for
parametric and nonparametric data, respectively. Categorical
data was analysed using Fisher’s exact test for two variables
and a chi-squared (χ2) test used when greater than two
groups were analysed. All tests were two-tailed with results
considered signiﬁcant if p < 0 05.
3. Results
3.1. Participant Characteristics. 39 patients with sepsis, 60
patients with severe sepsis, and 21 age-matched healthy con-
trols were recruited. Predictably, patients with sepsis had sig-
niﬁcantly greater comorbidities and were taking more
medications than healthy controls were. However, the
patients recruited into the sepsis and severe sepsis cohorts
were well matched with no signiﬁcant diﬀerences for age,
sex, preexisting diseases, or medications being taken. The
demographics of enrolled participants are shown in Table 1
with an experimental consort diagram shown in Figure 1.
3.2. Severe Sepsis, but Not Sepsis, Suppresses NET Production.
Ex vivo NETosis in healthy controls were compared to
patients diagnosed with sepsis and severe sepsis on admis-
sion to hospital. No diﬀerences were seen in baseline NETo-
sis in unstimulated neutrophils between groups (8219± 2796
AFUs versus 7219± 4685 AFUs versus 7191± 5141 AFUs;
ANOVA, p = 0 701). PMA-stimulated neutrophils from
healthy controls and from patients with sepsis generate sim-
ilar levels of NETs (healthy controls: 49659± 3285 AFUs ver-
sus sepsis: 45304± 1777 AFUs; Student’s t-test, p = 0 207;
Figure 2(a)). However, in neutrophils from patients with
severe sepsis, NETosis (37181± 2204 AFUs) was signiﬁcantly
abrogated compared to both healthy controls (49659± 3285
AFUs) and patients with sepsis (45304± 1777 AFUs;
ANOVA, p = 0 002; see Figure 2(a)). In a subgroup of
patients with severe sepsis that had septic shock (N = 13),
NETosis was further attenuated compared to the healthy
controls (23785± 2853 AFUs versus 49,659± 3285 AFUs;
Student’s t-test, p < 0 001) and patients with sepsis (23785
± 2853 AFUs versus 45304± 1777 AFUs, p < 0 001).
3.3. Persistent Attenuation of NETosis over Time. In patients
with sepsis and severe sepsis, dynamic changes in NETosis
were assessed on days 1, 4, and 7 where permitted (see
Figure 2(b)). Patients with sepsis (day 1: 45304± 11096 AFUs
versus day 4: 45081± 11047 versus day 7: 44871± 19480;
ANOVA, p = 0 99) and severe sepsis (day 1: 37181± 2204
AFUs versus day 4: 37513± 1954 AFUs versus day 7: 40116
± 2622 AFUs, ANOVA, p = 0 68) did not show any signiﬁ-
cant change in NETosis over time. On day 4, NETosis in
patients with severe sepsis (37513± 1954 AFUs, N = 39)
was signiﬁcantly lower compared to sepsis patients at day 4
(45081± 2017 AFUs,N = 30) and healthy controls at baseline
(ANOVA, p = 0 001; see Figure 2(b)). By day 7, despite most
patients with severe sepsis showing signs of sepsis resolution
(SOFA 0-1), NETosis was persistently reduced compared to
healthy controls (40116± 2622 AFUs versus 49659± 3285
AFUs; Student’s t-test, p = 0 02; see Figure 2(b)). Neutrophils
fromnonresolvingdonorsof sepsisbyday7 (SOFA > 3,N = 9)
showed a trend towards generating a lower number of
NETs compared with resolvers and healthy aged controls
(39347± 6103 versus 42545± 2502 versus 49659± 3285),
but this failed to reach signiﬁcance (p = 0 17, ANOVA). To
detect a signiﬁcant diﬀerence, with 80% power (p = 0 05), a
total of 29patientswithnonresolving sepsiswouldbe required.
3.4. Suppressed NETosis Is Associated with Increased Early
and Late Mortality. Amongst all patients admitted with sep-
sis and severe sepsis, 16 died within 30 days of admission,
with 80 surviving. Survivors of sepsis/severe sepsis had
greater PMA-induced NETosis on admission than nonsurvi-
vors had (47153± 1559 AFUs versus 34241± 4666 AFUs;
Student’s t-test p = 0 002; see Figure 3). By 90 days, mortality
had risen to 24 patients and again was associated with an
attenuated NETosis at admission to hospital (46772± 1744
versus 37498± 3602 AFUs; Student’s t test, p = 0 014). There
were no signiﬁcant diﬀerences between survivors and non-
survivors with regard to age at 30 days or 90 days.
The receiver operator curve (ROC) of survivors and non-
survivors demonstrated an area under the curve of 0.70 (95%
CI: 0.56–0.86; p = 0 011) with admission PMA-induced NET
value of less than 39000 AFUs, having a 56% sensitivity and a
71% speciﬁcity for predicting 30-day mortality, whilst for 90-
day mortality there was a 47% sensitivity and 70% speciﬁcity.
3.5. Suppression of NETosis Is Related to the Severity of
Acidosis. The standardized base excess (SBE) is a measure
of metabolic acidosis. Patients with severe sepsis had a lower
average SBE than those with sepsis had, who had a lower
average SBE than healthy controls. Patients with greater
deﬁcits in measured SBE, reﬂecting a more severe metabolic
acidosis, demonstrated a reduction in NETosis (Spearman
rho = 0 348, 95% CI 0.147–0.521, p < 0 001) (see Figure 4).
We therefore hypothesized that the acidosis induced by
sepsis may alter neutrophil functions and be causally
associated with the reduction of NETosis seen in patients
with severe sepsis.
To investigate this, neutrophils from healthy donors were
incubated in media (RPMI 1640) at a range of pathophysio-
logical pHs (pH7.4, 7.2, and 7.0) for 40 minutes prior to
NETosis experiments being carried out as described previ-
ously. As the pH of the control media was reduced, there
was a sequential fall in healthy donor neutrophils’ ability to
generate NETs in response to PMA stimulation (see
Figure 4), although signiﬁcance was only seen when compar-
ing a pH of 7.4 with 7.0. Viability assays performed demon-
strated no signiﬁcant alteration in neutrophil viability
induced by changes in pH at 4 hours.
3.6. Cell-Free DNA Is Raised in Patients with Sepsis. Circulat-
ing levels of plasma cf-DNA were measured on patients
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where sequential data points were available. Patients with
sepsis (1308ng/ml) and severe sepsis (1801 ng/ml) had sig-
niﬁcantly elevated levels of cf-DNA (ANOVA, p < 0 001)
on admission compared to healthy controls (69 ng/ml) which
persisted through to day 7 (ANOVA, p < 0 001) following
admission (see online Supplementary Materials). No correla-
tion was observed between NETosis and plasma cf-DNA
(p = 0 988, Spearman’s rho).
Table 1: Characteristics of healthy controls and patients with sepsis and severe sepsis enrolled in the study.
Healthy controls Sepsis Severe sepsis Septic shock p value
N 21 39 60 13
Age
70 75 73 71
0.519∗
(66–77) (65–85) (60–84) (48–74)
Sex, male (%) 13 (61.9) 20 (51.3) 41 (68.3) 10 (76.9) 0.070#
No. of comorbidities
0 15 10 9 3
<0.001Φ1 6 17 21 5
2 0 7 19 3
3+ 0 5 11 2
Comorbidities§, n
None 15 (71) 10 (26) 9 (15) 3 (23)
0.076Φ
Hypertension 6 (29) 18 (46) 37 (62) 4 (31)
IHD 0 (0) 10 (26) 15 (25) 2 (15)
Asthma 0 (0) 0 (0) 0 (0) 1 (8)
COPD 0 (0) 14 (36) 21 (35) 0 (0)
Chronic renal disease 0 (0) 0 (0) 3 (5) 0 (0)
Diabetes 0 (0) 3 (8) 17 (28) 4 (31)
Medications§, n
None 15 15 10 3
<0.001Φ
Antihypertensive 6 6 28 2
Beta-blocker 1 8 16 3
Antiplatelet 0 13 16 2
Oral hypoglycemic 0 3 11 2
Insulin 0 0 6 4
Inhaled beta-agonist 0 6 16 0
HMG-CoA reductase inhibitors 0 8 20 3
APACHE II N/A 14.5 (9–16) 16 (14–19) 19 (14–23) <0.001
ICU Admission, N N/A 0 (0%) 14 (23.3%) 13 (100%)
N/A
Vasopressors alone 2 2
Respiratory support 4 3
Multiorgan support 8 8
WCC (109/l) 14.8 (12.3–19.0) 15.1 (12.6–19.8) 20.4 (10.2–26.3) 0.634∗∗
CRP (mg/l) 153 (54.5–247) 100 (23.7–264) 132 (95–291) 0.232∗∗
Lactate (nM) N/A 1.7 (1.1–2.1) 2.5 (2.0–3.4) 2.6 (1.3–4.1) <0.001∗∗
SBE N/A 0.2 (−1.2 to 2.6) −2.2 (−5.6 to 0.5) −4.0 (−7.2 to −2.2) 0.001∗∗
SOFA score N/A 1 (0-1) 3 (1–6) 9 (6–12) <0.001∗∗
Length of stay, days N/A 10 (6–19) 10 (6.3–19.8) 21.5 (10–67) 0.505∗∗
Mortality, n (%)
30-day 0 4 (10) 12 (20) 7 (53) 0.265#
90-day 0 7 (18) 17 (28) 8 (62) 0.337#
360-day 0 11 (28) 22 (37) 8 (62) 0.513#
The baseline characteristics of healthy participants and patients recruited. The septic shock cohort is a subset of the patients with severe sepsis. The p values have
been calculated using healthy, sepsis, and severe sepsis participant cohorts where appropriate. p values represented by ∗ are from a Kruskal-Wallis test, # from a
Fisher’s exact test, Φ from a χ2 test, and ∗∗ from a Mann–Whitney U test.
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3.7. Severe Sepsis Causes Aberrant Neutrophil Migration.
Chemotaxis (directional migration) towards CXCl-8 on
admission in patients with severe sepsis (0.15μm/min,
IQR 0.01–0.43μm/min) was signiﬁcantly reduced com-
pared to patients with sepsis (0.49μm/min, IQR 0.19–
0.93μm/min) and healthy age-matched donor neutrophils
(0.86μm/min {IQR 0.40–1.8μm/min}, Kruskal-Wallis;
p < 0 001). Although patients with sepsis (without organ dys-
function) showed reduced chemotaxis compared to healthy
controls, this failed to reach statistical signiﬁcance (Dunn’s;
p = 0 15). Dysfunctional chemotaxis in severe sepsis patients
(N = 32) persisted through to day 4 (0.35μm/min {IQR 0.09–
0.85μm/min} versus 0.86μm/min {IQR 0.40–1.8μm/min};
Dunn’s; p = 0 021). By day 7, chemotaxis in severe sepsis
patients (N = 21) remained below levels seen in healthy
elderly donors (0.60μm/min {IQR 0.30–1.1μm/min} versus
0.86μm/min {IQR 0.40–1.8μm/min}), but this failed to
reach signiﬁcance (Dunn’s; p = 0 15).
3.8. Apoptosis Is Delayed in Neutrophils from Sepsis Patients.
Neutrophil apoptosis from 18 patients with severe sepsis and
19 age-matched healthy controls was measured at the time of
neutrophil isolation, at 4 hours and 24 hours postisolation.
Patients with severe sepsis patients had a greater number of
neutrophils in early (18.8% {IQR 13–32%} versus 5.3%
{IQR 3.9–6.7%} p < 0 001, Mann–Whitney U test) and late
apoptosis (2.8% {IQR 1.0–3.6%} versus 1.2% {IQR 0.5–
2.1%} p = 0 03, Mann–Whitney U test) compared to healthy
controls at the time of isolation.
At 4 hours, neutrophils from severe sepsis patients
showed no diﬀerence in early and late apoptosis compared
to baseline (early: 19.6% {IQR 15–33%} versus 18.8% {IQR
12–32%}, p = 0 19; late: 2.8% {1.0 versus 3.3% versus 2.6%
{1.3–4.0} p = 0 45, Wilcoxon signed-rank tests), whilst
healthy neutrophils showed signiﬁcant increased early
apoptosis 4 hours following isolation (10.2% {IQR 8–12%)
versus 5.3% {IQR 3.6–5.8%}, Wilcoxon signed-rank test;
p < 0 001).
At 24 hours following isolation, the rates of early
(34.9± 22% versus 67.4± 15%, p < 0 001) and late apoptosis
(9.4± 2.3% versus 19.8± 1.7%, p = 0 002) were signiﬁcantly
lower in severe sepsis patients compared with healthy
patients, suggesting that neutrophil survival is prolonged
during sepsis.
99 patients recruited
60 severe sepsis patients
60 NET experiments
42 chemotaxis experiments
39 sepsis patients
39 NET experiments
28 chemotaxis experiments
39 severe sepsis patients
39 NET experiments
32 chemotaxis experiments
30 sepsis patients
30 NET experiments
18 chemotaxis experiments
29 severe sepsis patients
29 NET experiments
21 chemotaxis experiments
21 sepsis patients
21 NET experiments
14 chemotaxis experiments
Day 1
Day 4
Day 7
3 refused blood sampling
4 died
15 were discharged
2 refused blood
sampling
3 died
4 were discharged
2 refused blood sampling
7 were discharged
4 refused blood
sampling
1 died
4 were discharged
Figure 1: Consort diagram of experiments. Modiﬁed consort diagram of the number of experiments performed at the various time points
during the study. The reducing number of experiments performed between the groups was due to either deaths, discharges from hospital,
or refusals of blood sampling from patients.
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4. Discussion
This study investigated the sequential changes in neutrophil
functions including NETosis and migration in a large cohort
of sepsis and severe sepsis patients and related this to clini-
cally relevant outcomes. Conﬁrming our initial hypothesis,
we demonstrated that severe sepsis is associated with a reduc-
tion in NETosis in systemic neutrophils which is not present
in milder forms of sepsis. Furthermore, in severe sepsis,
reduced NETosis persists through to days 4 and 7. Reduced
NETosis was associated with important clinical outcomes
including short- (30-day) and medium-term (90-day) mor-
tality. To our knowledge, this is the largest study of NETosis
in sepsis and the ﬁrst that reports a relationship with impair-
ment in innate immune cell function and patient survival.
Suppression of ex vivo NETosis below 39000 AFUs was per-
formed comparatively with other traditional biomarkers in
predicting mortality from sepsis such as the severity of acido-
sis (SBE) and lactate [30].
We also observed a correlation between the severity of
acidosis and the attenuation of NETosis in patients with sep-
sis. Furthermore, by manipulating the pH of the cellular envi-
ronment in vitro, we could recapitulate the septic neutrophil
phenotype suggesting that the disruption of cellular acid-base
homeostasis may contribute to dysfunctional NETosis and
perhaps other neutrophil functions. Changes in extracellular
pH are common in many inﬂammatory diseases and lead to
neutrophil activation, phagocytosis, and ROS production
[31, 32]. NET formation in relation to pH has not been stud-
ied before, and these data add to the literature of the negative
impact of acid-base disturbance.
Our data suggest that sepsis and the associated inﬂamma-
tion and changes in blood pH may induce a neutrophil phe-
notype characterised by poor migratory accuracy, reduced
NETosis, and prolonged neutrophil survival. Previously, we
have described aberrant neutrophil migratory accuracy with
sepsis in pneumonia, but the current study is the ﬁrst to study
neutrophil functions and survival in such a large cohort of
sepsis patients [12].
NETosis is a terminal event for neutrophils; thus, neutro-
phil activation and predominance of antiapoptotic pathways
induced with sepsis may inhibit NETosis [31–33]. However,
NETosis studies in patients with sepsis are hindered due to
the failure to capture early NETosis at sepsis onset. Our study
describes no diﬀerence in baseline NET release but reduced
NET release following activation in patients with severe sepsis
60000
p = 0.002⁎
p = 0.022⁎
40000
20000
0
Healthy controls Sepsis
Sepsis
Severe sepsis
Severe sepsis
N
ET
 p
ro
du
ct
io
n 
(A
FU
s)
(a)
60000
50000
40000
30000
Control Day 4 Day 7
p = 0.002⁎
p = 0.02⁎
p = 0.04⁎
N
ET
 p
ro
du
ct
io
n 
(A
FU
s)
Sepsis
Severe sepsis
(b)
Figure 2: The ex vivo production of NETs in healthy controls and patients with sepsis and severe sepsis. (a) NETosis from 21 healthy controls,
39 patients with sepsis, and 60 patients with severe sepsis following stimulation with 25 nM PMA for 4 hours ex vivo. An ANOVA between all
3 groups showed a signiﬁcant diﬀerence where p = 0 002, with ∗ representing the signiﬁcant diﬀerences in a post hoc Tukey’s test. (b)
NETosis from 21 healthy controls, 30 patients with sepsis, and 39 patients with severe sepsis on day 4 following stimulation with 25 nM
PMA for 4 hours ex vivo. An ANOVA between all 3 groups showed a signiﬁcant diﬀerence (p = 0 001), with ∗ representing signiﬁcant
diﬀerences in a post hoc Tukey’s test. On day 7, there are 21 sepsis patients and 29 severe sepsis patients. There was a signiﬁcant
diﬀerence between healthy controls and patients with severe sepsis∗∗.
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Figure 3: PMA-induced NET release is lower in nonsurvivors of
sepsis at 30 days and 90 days. NET production in recruited
patients on enrollment in response to PMA in survivors and
nonsurvivors of sepsis at 30 days, 90 days, and 360 days following
admission. Bars represent the mean with error bars the SEM, with
p values from a Student’s t-test.
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which does not recover at day 4 or 7 and a high burden of cf-
DNA.Theseﬁndings appear contradictory but are concordant
with other studies of neutrophil function following a major
host insult [34]. It has been proposed that the “ﬁrst wave” of
neutrophils to arrive at sites of infection is programmed for
early NETosis in an attempt to contain the infection rapidly
[35]. Those arriving later (which form the circulating pool on
testing) may be activated by circulating cytokines and the
septic environment and are resistant to apoptosis accounting
for the attenuation of NETosis observed [32, 36].
The high levels of cell-free DNAwould be consistent with
evidence of an accumulation of NETs in inﬂammatory con-
ditions caused by poor clearance [37]. Sepsis is associated
with increased complement activity, and studies have shown
that NETs activate the complement in vitro and deposited
C1q inhibits NET degradation including a direct inhibition
of DNase-I by C1q [38]. Clearance of nets may also be
delayed due to suppression of DNases by renal/hepatic dys-
function present in multiorgan dysfunction [39]. This pro-
vides a potential mechanism for the presence of increased
cell-free DNAwith circulating neutrophils which are less able
to undergo NETosis, as described in the current study and
others [29, 40]. Cf-DNA is also gaining increasing attention,
as a potential biomarker in sepsis, as it predicts outcomes
from sepsis in patients admitted to intensive care and is rela-
tively easy to measure [39, 41, 42]. However, more work is
needed to determine the relationship of cf-DNA to cell func-
tions and clinical outcomes.
The changes in neutrophil phenotype may drive further
local and distant organ damage and predispose patients to
secondary infections by inducing a state of immunosuppres-
sion [32, 43]. We propose a biphasic neutrophilic response to
infection, with initial activation leading to migratory failure,
frustrated phagocytosis, a release of large quantities of NETs,
seen as cf-DNA, and a subsequent prolongation of neutrophil
survival. The circulation of these free histones would activate
the adaptive immune system, via dendritic cells, with the
formation of anti-elastin, anti-histone, and anti-nuclear
antibodies, as described in chronic inﬂammatory illnesses
and autoimmune diseases, leading to further endothelial
damage and exacerbating microcirculatory dysfunction
[44, 45]. Sepsis-induced immunosuppression is also propa-
gated by neutrophils that induce apoptosis in T-cells via
the programmed death receptor and its ligand (PD-1/
PD-L1) [8, 46, 47].
This study has limitations. Firstly, not all patients could
have samples taken for analysis at all time points leading to
the disparity in numbers across time points and assays.
Patients with sepsis often experience a ﬂuctuating course in
their clinical recovery and require serial clinical blood tests,
and missing time points are a common feature of studies of
this nature [48, 49]. However, there were no diﬀerences in
patient characteristics in all substudies to the main group,
suggesting the data is representative of all patients.
Presepsis neutrophil function has not been assessed in
these patients, and it is unclear whether preexisting neutro-
phil dysfunction is pathogenically associated with sepsis; it
is possible that those with poorest outcomes had worse base-
line neutrophil function. In survivors of the initial infectious
insult, further neutrophil functions were not assessed beyond
7 days and so it is unclear if neutrophil function returns to
levels expected in health following complete resolution or
whether a permanent dysfunction results, predisposing these
patients to further infectious insults.
A further limitation is the use of PMA as the stimulant to
generate NETs. PMA is not physiological but causes maximal
release of ROS and subsequently NETs by circumventing G
receptor signaling [13]. This stimulus was chosen to assess
maximal NET release, and similar concentrations have been
used in several NET-related publications, enabling compari-
sons with published literature [13, 29, 40, 50].
5. Conclusions
Sepsis induces signiﬁcant changes in neutrophil function.
These may contribute to the failure of containment and the
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Figure 4: The impact of acidosis on neutrophil extracellular trap formation. (a) Correlation between standardized base excess and neutrophil
extracellular trap formation in 99 patients with sepsis. Spearman’s rho suggests that reduction in NET formation is associated with worsening
acidosis. (b) Eﬀect of acidosis on the NETs generated from the neutrophils of 5 healthy donors.
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dissemination of the infection, whilst exaggerating the dys-
regulated immune response that is the hallmark of sepsis
[4]. We propose that the combined dysfunctions result in a
phenotypic immunoparesed neutrophil that contributes to
the high mortality in patients with sepsis. Finally, we propose
that further investigation into NETosis and cf-DNA as
potential future biomarkers to identify high-risk patients
with sepsis is warranted.
Abbreviations
AFUs: Arbitrary ﬂuorescent units
ANOVA: Analysis of variance
cf-DNA: Cell-free DNA
CXCL-8: Interleukin-8
GPS: Glutamine, penicillin, and streptomycin
IQR: Interquartile range
NET: Neutrophil extracellular trap
PD-1: Programmed death receptor-1
PMA: Phorbol-myristate acetate
ROS: Reactive oxygen species
SBE: Standardized base excess
SEM: Standard error of the mean
USA: United States of America.
Data Availability
The datasets used and/or analysed during the current
study are available from the corresponding author on
reasonable request.
Ethical Approval
Ethical approval for the study was granted by the Yorkshire
and Humber regional ethics committee (references: 11/SC/
0356 and 11/YH/0270).
Consent
All patients and participants in this study provided
informed consent. Where consent was not possible, assent
from their next of kin or an appropriate professional consul-
tee was sought. Retrospective consent was later conﬁrmed
where possible.
Disclosure
Jaimin M. Patel and Elizabeth Sapey are joint ﬁrst authors.
Conflicts of Interest
The authors declare that they have no competing interests.
Authors’ Contributions
Jaimin M. Patel, David R. Thickett, Fang Gao, and Elizabeth
Sapey designed the study and undertook the analysis. Jaimin
M. Patel, Dhruv Parekh, and Davinder Dosanjh undertook
the patient recruitment, sample analysis, and laboratory
work. Aaron Scott conducted the sample analysis. Jaimin
M. Patel, Elizabeth Sapey, and David R. Thickett wrote the
ﬁrst draft. All authors have reviewed and approved the ﬁnal
version of paper.
Acknowledgments
Dhruv Parekh, Aaron Scott, and David R. Thickett were
supported by the UK Medical Research Council. Fang Gao
is a NIHR senior investigator. Elizabeth Sapey was supported
by the British Lung Foundation and UK Medical Research
Council. Jaimin M. Patel was supported by the NIAA.
Supplementary Materials
Table 1: criteria used for the deﬁnition of patients with sepsis
and severe sepsis. Table 2: cell-free DNA values in healthy
controls and sepsis and severe sepsis patients at days 1 and
7. Figure 1: severe sepsis is associated with reduced chemo-
taxis. (A) The diﬀerence in chemotaxis between healthy aged
controls, sepsis patients, and severe sepsis patients on admis-
sion to hospital. (B) Sequential changes in neutrophil chemo-
taxis in patients with sepsis (day 1 N=28, day 4 N=18, and
day 7 N=14) and severe sepsis (day 1 N=42, day 4 N=32,
and day 7 N=21). Bars represent the median and IQR with
the error bars from Tukey’s distribution. p values from a
Kruskal-Wallis test. (Supplementary Materials)
References
[1] D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont,
J. Carcillo, and M. R. Pinsky, “Epidemiology of severe sepsis
in the United States: analysis of incidence, outcome, and asso-
ciated costs of care,” Critical Care Medicine, vol. 29, no. 7,
pp. 1303–1310, 2001.
[2] D. C. Angus and T. van der Poll, “Severe sepsis and septic
shock,” The New England Journal of Medicine, vol. 369,
no. 9, pp. 840–851, 2013.
[3] N. K. J. Adhikari, R. A. Fowler, S. Bhagwanjee, and G. D.
Rubenfeld, “Critical care and the global burden of critical ill-
ness in adults,” Lancet, vol. 376, no. 9749, pp. 1339–1346,
2010.
[4] M. Singer, C. S. Deutschman, C. W. Seymour et al., “The Third
International Consensus Deﬁnitions for Sepsis and Septic
Shock (Sepsis-3),” JAMA, vol. 315, no. 8, pp. 801–810, 2016.
[5] R. S. Hotchkiss and I. E. Karl, “The pathophysiology and treat-
ment of sepsis,” The New England Journal of Medicine,
vol. 348, no. 2, pp. 138–150, 2003.
[6] N. Borregaard, “Neutrophils, from marrow to microbes,”
Immunity, vol. 33, no. 5, pp. 657–670, 2010.
[7] K. A. Brown, S. D. Brain, J. D. Pearson, J. D. Edgeworth, S. M.
Lewis, and D. F. Treacher, “Neutrophils in development of
multiple organ failure in sepsis,” Lancet, vol. 368, no. 9530,
pp. 157–169, 2006.
[8] P. H. C. Leliefeld, C. M. Wessels, L. P. H. Leenen,
L. Koenderman, and J. Pillay, “The role of neutrophils in
immune dysfunction during severe inﬂammation,” Critical
Care, vol. 20, no. 1, p. 73, 2016.
[9] J. C. Alves-Filho, A. de Freitas, F. Spiller, F. O. Souto, and F. Q.
Cunha, “The role of neutrophils in severe sepsis,” Shock,
vol. 30, Supplement 1, pp. 3–9, 2008.
8 Mediators of Inﬂammation
[10] M. J. Delano, T. Thayer, S. Gabrilovich et al., “Sepsis induces
early alterations in innate immunity that impact mortality to
secondary infection,” Journal of Immunology, vol. 186, no. 1,
pp. 195–202, 2011.
[11] L. Fialkow, L. Fochesatto Filho, M. C. Bozzetti et al., “Neutro-
phil apoptosis: a marker of disease severity in sepsis and sepsis-
induced acute respiratory distress syndrome,” Critical Care,
vol. 10, no. 6, p. R155, 2006.
[12] E. Sapey, J. M. Patel, H. L. Greenwood et al., “Pulmonary infec-
tions in the elderly lead to impaired neutrophil targeting,
which is improved by simvastatin,” American Journal of
Respiratory and Critical Care Medicine, vol. 196, no. 10,
pp. 1325–1336, 2017.
[13] V. Brinkmann, U. Reichard, C. Goosmann et al., “Neutrophil
extracellular traps kill bacteria,” Science, vol. 303, no. 5663,
pp. 1532–1535, 2004.
[14] V. I. Landoni, P. Chiarella, D. Martire-Greco et al., “Tolerance
to lipopolysaccharide promotes an enhanced neutrophil extra-
cellular traps formation leading to a more eﬃcient bacterial
clearance in mice,” Clinical and Experimental Immunology,
vol. 168, no. 1, pp. 153–163, 2012.
[15] P. Li, M. Li, M. R. Lindberg, M. J. Kennett, N. Xiong, and
Y. Wang, “PAD4 is essential for antibacterial innate immunity
mediated by neutrophil extracellular traps,” The Journal of
Experimental Medicine, vol. 207, no. 9, pp. 1853–1862, 2010.
[16] M. Arazna, M. P. Pruchniak, and U. Demkow, “Neutrophil
extracellular traps in bacterial infections: strategies for escap-
ing from killing,” Respiratory Physiology & Neurobiology,
vol. 187, no. 1, pp. 74–77, 2013.
[17] W. Meng, A. Paunel-Gorgulu, S. Flohe et al., “Depletion of
neutrophil extracellular traps in vivo results in hypersuscepti-
bility to polymicrobial sepsis in mice,” Critical Care, vol. 16,
no. 4, p. R137, 2012.
[18] T. Narasaraju, E. Yang, R. P. Samy et al., “Excessive neutro-
phils and neutrophil extracellular traps contribute to acute
lung injury of inﬂuenza pneumonitis,” The American Journal
of Pathology, vol. 179, no. 1, pp. 199–210, 2011.
[19] S. R. Clark, A. C. Ma, S. A. Tavener et al., “Platelet TLR4 acti-
vates neutrophil extracellular traps to ensnare bacteria in sep-
tic blood,” Nature Medicine, vol. 13, no. 4, pp. 463–469, 2007.
[20] E. E. Gardiner and R. K. Andrews, “Neutrophil extracellular
traps (NETs) and infection-related vascular dysfunction,”
Blood Reviews, vol. 26, no. 6, pp. 255–259, 2012.
[21] G.M. Thomas, C. Carbo, B. R. Curtis et al., “Extracellular DNA
traps are associated with the pathogenesis of TRALI in humans
and mice,” Blood, vol. 119, no. 26, pp. 6335–6343, 2012.
[22] E. Villanueva, S. Yalavarthi, C. C. Berthier et al., “Netting
neutrophils induce endothelial damage, inﬁltrate tissues, and
expose immunostimulatory molecules in systemic lupus ery-
thematosus,” Journal of Immunology, vol. 187, no. 1,
pp. 538–552, 2011.
[23] R. P. Dellinger, M. M. Levy, J. M. Carlet et al., “American Asso-
ciation of Critical-Care Nurses, American College of Chest
Physicians, American College of Emergency Physicians.,
Canadian Critical Care Society., European Society of Clinical
Microbiology and Infectious Diseases., European Society of
Intensive Care Medicine., European Respiratory Society.,
International Sepsis Forum., Japanese Association for Acute
Medicine., Japanese Society of Intensive Care Medicine., Soci-
ety of Critical Care Medicine., Society of Hospital Medicine.,
Surgical Infection Society., World Federation of Societies of
Intensive and Critical Care Medicine. Surviving sepsis
campaign: international guidelines for management of severe
sepsis and septic shock: 2008,” Critical Care Medicine,
vol. 36, no. 1, pp. 296–327, 2008.
[24] S. K. Butcher, H. Chahal, L. Nayak et al., “Senescence in innate
immune responses: reduced neutrophil phagocytic capacity
and CD16 expression in elderly humans,” Journal of Leukocyte
Biology, vol. 70, no. 6, pp. 881–886, 2001.
[25] E. Sapey, H. Greenwood, G. Walton et al., “Phosphoinositide
3-kinase inhibition restores neutrophil accuracy in the elderly:
toward targeted treatments for immunosenescence,” Blood,
vol. 123, no. 2, pp. 239–248, 2014.
[26] J. Hazeldine, P. Harris, I. L. Chapple et al., “Impaired neutro-
phil extracellular trap formation: a novel defect in the innate
immune system of aged individuals,” Aging Cell, vol. 13,
no. 4, pp. 690–698, 2014.
[27] N. Andrew and R. H. Insall, “Chemotaxis in shallow gradients
is mediated independently of PtdIns 3-kinase by biased
choices between random protrusions,” Nature Cell Biology,
vol. 9, no. 2, pp. 193–200, 2007.
[28] E. Sapey, J. A. Stockley, H. Greenwood et al., “Behavioral and
structural diﬀerences in migrating peripheral neutrophils from
patients with chronic obstructive pulmonary disease,” Ameri-
can Journal of Respiratory and Critical Care Medicine,
vol. 183, no. 9, pp. 1176–1186, 2011.
[29] P. Hampson, R. J. Dinsdale, C. M. Wearn et al., “Neutrophil
dysfunction, immature granulocytes, and cell-free DNA are
early biomarkers of sepsis in burn-injured patients; a prospec-
tive observational cohort study,” Annals of Surgery, vol. 265,
no. 6, pp. 1241–1249, 2017.
[30] I. Smith, P. Kumar, S. Molloy et al., “Base excess and lactate as
prognostic indicators for patients admitted to intensive care,”
Intensive Care Medicine, vol. 27, no. 1, pp. 74–83, 2001.
[31] A. S. Trevani, G. Andonegui, M. Giordano et al., “Extracellular
acidiﬁcation induces human neutrophil activation,” Journal of
Immunology, vol. 162, no. 8, pp. 4849–4857, 1999.
[32] F. E. Diaz, E. Dantas, M. Cabrera et al., “Fever-range hyper-
thermia improves the anti-apoptotic eﬀect induced by low
pH on human neutrophils promoting a proangiogenic proﬁle,”
Cell Death & Disease, vol. 7, no. 10, article e2437, 2016.
[33] J. G.Wann, Y.H.Hsu, C. C. Yang et al., “Neutrophils in acidotic
haemodialysed patients have lower intracellular pH and
inﬂamed state,” Nephrology, Dialysis, Transplantation, vol. 22,
no. 9, pp. 2613–2622, 2007.
[34] J. Hazeldine, D. N. Naumann, E. Toman et al., “Prehospital
immune responses and development of multiple organ
dysfunction syndrome following traumatic injury: a prospec-
tive cohort study,” PLoS Medicine, vol. 14, no. 7, article
e1002338, 2017.
[35] B. G. Yipp and P. Kubes, “NETosis: how vital is it?,” Blood,
vol. 122, no. 16, pp. 2784–2794, 2013.
[36] G. Drifte, I. Dunn-Siegrist, P. Tissieres, and J. Pugin, “Innate
immune functions of immature neutrophils in patients with
sepsis and severe systemic inﬂammatory response syndrome,”
Critical Care Medicine, vol. 41, no. 3, pp. 820–832, 2013.
[37] A. Mahajan, M. Herrmann, and L. E. Munoz, “Clearance deﬁ-
ciency and cell death pathways: a model for the pathogenesis of
SLE,” Frontiers in Immunology, vol. 7, 2016.
[38] J. Leﬄer, M. Martin, B. Gullstrand et al., “Neutrophil extracel-
lular traps that are not degraded in systemic lupus erythemato-
sus activate complement exacerbating the disease,” Journal of
Immunology, vol. 188, no. 7, pp. 3522–3531, 2012.
9Mediators of Inﬂammation
[39] K. Saukkonen, P. Lakkisto, V. Pettila et al., “Cell-free plasma
DNA as a predictor of outcome in severe sepsis and septic
shock,” Clinical Chemistry, vol. 54, no. 6, pp. 1000–1007,
2008.
[40] M. Hashiba, A. Huq, A. Tomino et al., “Neutrophil extracellu-
lar traps in patients with sepsis,” The Journal of Surgical
Research, vol. 194, no. 1, pp. 248–254, 2015.
[41] R. Huttunen, T. Kuparinen, J. Jylhava et al., “Fatal outcome in
bacteremia is characterized by high plasma cell free DNA con-
centration and apoptotic DNA fragmentation: a prospective
cohort study,” PLoS One, vol. 6, no. 7, article e21700, 2011.
[42] S. Margraf, T. Logters, J. Reipen, J. Altrichter, M. Scholz,
and J. Windolf, “Neutrophil-derived circulating free DNA
(cf-DNA/NETs): a potential prognostic marker for posttrau-
matic development of inﬂammatory second hit and sepsis,”
Shock, vol. 30, no. 4, pp. 352–358, 2008.
[43] J. K. Juss, D. House, A. Amour et al., “Acute respiratory distress
syndrome neutrophils have a distinct phenotype and are resis-
tant to phosphoinositide 3-kinase inhibition,” American
Journal of Respiratory and Critical Care Medicine, vol. 194,
no. 8, pp. 961–973, 2016.
[44] A. P. Diamantopoulos, “Extracellular neutrophil traps: a novel
therapeutic target in ANCA-associated vasculitis?,” Frontiers
in Immunology, vol. 4, 2013.
[45] K. Tillack, P. Breiden, R. Martin, andM. Sospedra, “T lympho-
cyte priming by neutrophil extracellular traps links innate and
adaptive immune responses,” Journal of Immunology, vol. 188,
no. 7, pp. 3150–3159, 2012.
[46] J. Demaret, F. Venet, A. Friggeri et al., “Marked alterations of
neutrophil functions during sepsis-induced immunosuppres-
sion,” Journal of Leukocyte Biology, vol. 98, no. 6, pp. 1081–
1090, 2015.
[47] A. C. Patera, A. M. Drewry, K. Chang, E. R. Beiter, D. Osborne,
and R. S. Hotchkiss, “Frontline science: defects in immune
function in patients with sepsis are associated with PD-1 or
PD-L1 expression and can be restored by antibodies targeting
PD-1 or PD-L1,” Journal of Leukocyte Biology, vol. 100, no. 6,
pp. 1239–1254, 2016.
[48] J. M. Patel, C. Snaith, D. R. Thickett et al., “Randomized
double-blind placebo-controlled trial of 40 mg/day of atorva-
statin in reducing the severity of sepsis in ward patients
(ASEPSIS Trial),” Critical Care, vol. 16, no. 6, p. R231, 2012.
[49] T. R. Craig, M. J. Duﬀy, M. Shyamsundar et al., “A randomized
clinical trial of hydroxymethylglutaryl-coenzyme a reductase
inhibition for acute lung injury (the HARP Study),” American
Journal of Respiratory and Critical Care Medicine, vol. 183,
no. 5, pp. 620–626, 2011.
[50] V. Brinkmann, B. Laube, U. Abu Abed, C. Goosmann, and
A. Zychlinsky, “Neutrophil extracellular traps: how to generate
and visualize them,” Journal of Visualized Experiments, no. 36,
article e1724, 2010.
10 Mediators of Inﬂammation
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
